The content discusses the U.S. Supreme Court’s decision to reject a challenge to government rules on abortion drugs, potential attacks on access in the future, and concerns about medical complications. Additionally, it mentions an increase in employer health plans covering GLP-1 drugs for diabetes management and weight loss. The survey showed an increase in coverage for weight loss, with some employers considering offering the drugs for this purpose. The article is exclusive to STAT+ subscribers and provides in-depth analysis, newsletters, and networking platform access. It also encourages readers to subscribe for unlimited access to journalism and exclusive events.
Source link
Ozempic, $35 insulin, abortion pill updates
